ACA vs NBIX · P/E 57, rev $2.88B vs P/E 45, rev $2.36B
Arcosa Inc (ACA) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Arcosa Inc (ACA) is a engineering & construction company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ACA revenue for 2025-12-31 was $2.88B. Net income was $208.4M. Revenue was up 12.2% from 2024-12-31 to 2025-12-31. ACA currently screens at market cap $4.39B and trailing P/E 56.6.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ACA currently screens at market cap $4.39B and trailing P/E 56.6. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ACA and NBIX stock pages for the full models.
Not investment advice.